Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 2,206 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control I Clear all
Completed Phase 3 Interventional

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

NCT04314544
View directory record Official record
Conditions
Active Psoriatic Arthritis
Interventions
TILD, matching placebo injections
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
45
States / cities
Dothan, Alabama • Gilbert, Arizona • Glendale, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 24, 2026, 2:43 PM EDT
Terminated Phase 1Phase 2 Interventional

Use of Oxandrolone to Promote Growth in Infants With HLHS

NCT04090697
View directory record Official record
Conditions
Hypoplastic Left Heart, Congenital Heart Disease
Interventions
Oxandrolone
Drug
Lead sponsor
Carelon Research
Other
Eligibility
Up to 14 Days
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 24, 2026, 2:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

NCT04333706
View directory record Official record
Conditions
Breast, Metastatic, Triple Negative, Cancer, Disseminated Tumor Cell
Interventions
Capecitabine, Sarilumab 150mg or 200 mg plus Capecitabine, Sarilumab 150mg plus Capecitabine
Drug · Combination Product
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 99 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 3 Interventional Results available

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

NCT01376349
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
prasterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
280
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 24, 2026, 2:43 PM EDT
Not listed Phase 3 Interventional

CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1

NCT02504008
View directory record Official record
Conditions
Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy
Interventions
AXS-02 (oral zoledronate), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
29
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Encinitas, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

IN Ketamine Vs IN Midazolam and Fentanyl for Abscess I&D

NCT02635282
View directory record Official record
Conditions
Abscess, Pain
Interventions
intranasal ketamine, intranasal fentanyl, intranasal midazolam
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
3 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra

NCT02270918
View directory record Official record
Conditions
Thrombosis
Interventions
Kcentra, Apixaban, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Not applicable Interventional Results available

Using Information Technology to Improve Asthma Adherence

NCT00459368
View directory record Official record
Conditions
Asthma, Patient Compliance
Interventions
Feedback of patient adherence information, Active control group
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
5 Years to 56 Years
Enrollment
2,698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

NCT04142424
View directory record Official record
Conditions
Metabolic Disorders, Non-alcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I, First-In-Human Study of TT-00920 in Healthy Subjects

NCT04364789
View directory record Official record
Conditions
Healthy
Interventions
TT-00920, Placebos
Drug
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 24, 2026, 2:43 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence

NCT04704050
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Fibrillation Recurrent
Interventions
dronedarone 400 mg Oral Tablet, Placebo
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Colorado Springs, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

NCT05592418
View directory record Official record
Conditions
Post COVID-19 Condition, Long COVID
Interventions
Rintatolimod, Placebo / Normal Saline
Drug · Other
Lead sponsor
AIM ImmunoTech Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
5
States / cities
Canoga Park, California • Inglewood, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 24, 2026, 2:43 PM EDT
Completed No phase listed Observational

Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1

NCT00339638
View directory record Official record
Conditions
Human T-Lymphoma Virus Type I
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 2:43 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

NCT07128615
View directory record Official record
Conditions
Influenza A
Interventions
AZD4117, AZD5315, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
14
States / cities
Long Beach, California • Rolling Hills Estates, California • Miami Lakes, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Not applicable Interventional Results available

A Positive Psychology Intervention for Patients With Multiple Sclerosis

NCT03637699
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Positive Psychology
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 24, 2026, 2:43 PM EDT
Recruiting Not applicable Interventional

The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer

NCT05780814
View directory record Official record
Conditions
Breast Cancer, Insomnia, Weight Gain
Interventions
Cognitive-Behavioral Therapy for Insomnia (CBT-I), Sleep Education Control (EDU)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 24, 2026, 2:43 PM EDT
Recruiting Phase 2 Interventional

ALTO-100 in Bipolar Disorder With Depression (BD-D)

NCT06656416
View directory record Official record
Conditions
Bipolar Disorder I or II With a Major Depressive Episode
Interventions
ALTO-100, Placebo
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
58
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Coenzyme Q-10 and Pulmonary Arterial Hypertension

NCT01148836
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Coenzyme Q-10 in Pulmonary Hypertension subjects, Coenzyme Q-10 in Normal Control subjects
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2015 · Synced Oct 24, 2026, 2:43 PM EDT
Terminated Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

NCT05660265
View directory record Official record
Conditions
Hematologic Diseases, Anaemia, Sickle Cell
Interventions
GSK4172239D, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Miami, Florida • Tamarac, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 24, 2026, 2:43 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC

NCT03370406
View directory record Official record
Conditions
Carcinoma, Squamous Cell
Interventions
5-fluorouracil, Calcipotriene
Drug
Lead sponsor
Melissa Pugliano-Mauro
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer

NCT02203552
View directory record Official record
Conditions
Anxiety Disorder, Depression, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
minocycline hydrochloride, placebo, laboratory biomarker analysis, Questionnaire administration
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of Thoracic Facet Joint Nerve Blocks

NCT00355706
View directory record Official record
Conditions
Low Back Pain
Interventions
Thoracic facet joint nerve blocks
Procedure
Lead sponsor
Pain Management Center of Paducah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Paducah, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults

NCT00294099
View directory record Official record
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
7
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 24, 2026, 2:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis

NCT06469164
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
BNT331, Placebo
Drug · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Marrero, Louisiana • Metairie, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 24, 2026, 2:43 PM EDT